Actinium Pharmaceuticals, Inc. ATNM 深 滬
已收盤 07-02 16:00:00 美东时间
0.981
+0.001
+0.12%
華盛通- 最 高0.99
- 今 開0.974
- 成交量 3.29万股
- 最 低 0.974
- 昨 收 0.9798
- 總市值 3077.89万
- 52周最高 1.89
- 市盈率 靜 --
- 換手率 0.10%
- 52周最低 0.94
- 委 比 33.33%
- 總股本 3137.50万
- 歷史最高 450.00
- 量 比 0.21
- 振 幅 1.63%
- 歷史最低 0.94
- 每 手 1
- 風險率 0.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Actinium Pharmaceuticals Obtains Two Patent Allowances Spanning Its Actimab-A And Iomab-ACT Programs
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Canadian Intellectual Property Office (CIPO) has issued Notices of
05-30 05:34
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
Together the allowances deepen protection across two priority franchises and reinforce a patent estate of approximately 250 issued and pending patents and patent applications worldwide NEW Y...
05-30 05:31
Actinium Highlights Data Presented At AACR Supporting Transcriptional Reprogramming As Central Mechanism Driving Mutation-Agnostic Anti-Leukemic Activity Of Actimab-A In AML
Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, independent of mutation status, when combined with standard-of-care targeted and non-targeted therapies including revumenib
04-22 19:08
Actinium Pharma Presents Preclinical Results For ATNM-400 Across Prostate, Lung, And Breast Cancer Models Presented At AACR Annual Meeting
ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potentialIn prostate cancer, ATNM-400 demonstrates efficacy across both high
04-22 19:06
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target
Stephens & Co. analyst Sudan Loganathan reiterates Actinium Pharma (AMEX:ATNM) with a Overweight and maintains $5 price target.
03-31 21:08
Actinium To Present Abstracts On ATNM-400 And Actimab-A Programs Across Solid Tumors And Hematologic Oncology Applications At AACR Annual Meeting 2026
AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology ApplicationsNEW YORK, Feb. 17, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)
02-17 20:46
Actinium Pharmaceuticals Steve O'Loughlin Resigns As CFO; Sandesh Seth Appointed As CFO
-SEC Filing
02-14 06:13
Actinium Pharma Advances Solid-Tumor Program With Phase 1 Clinical Trial In South Africa Targeting B7-H3
Actinium Pharmaceuticals (NYSE:ATNM), a company developing targeted alpha radiotherapies, is advancing its solid-tumor program with a Phase 1 clinical trial in South Africa targeting B7-H3. This study represents one of
2025-12-09 03:48
Actinium Pharma To Present Preclinical Data For ATNM-400, Actinium-225 Antibody Radioconjugate, In HR+, HER2+ And Triple-Negative Breast Cancer At SABCS 2025
Presentation to include new data in triple-negative disease, a breast cancer subtype with poor outcomes and limited viable treatment options ATNM-400 overcomes HER2 therapy resistance and represents a novel
2025-12-01 21:49
